Inclusion Criteria

Inclusion criteria:

- Histologically-confirmed stage III or IV ovarian carcinoma or primary peritoneal
cancer patients who have had appropriate debulking surgery for ovarian or peritoneal
carcinoma.

- Patients must be recovered from initial surgery and must enter this study no later
than 12 weeks after such surgery.

- ECOG performance score of 0, 1, or 2.

- absolute neutrophil count (ANC) at least 1,500/µL.

- platelet at least 100,000/µL.

- hemoglobin at least 10 g/dL.

- creatinine no greater than 1.5 times the upper limit of normal (ULN).

- bilirubin no greater than 1.5 x ULN (if liver metastases are not present, SGOT and
SGPT no greater than 2.5 x ULN, if liver metastases are present, SGOT and SGPT may be
no greater than 5 x ULN.

- Alkaline phosphatase no greater than 2.5 x ULN.

Exclusion:

- Current diagnosis of epithelial ovarian tumor of low malignant potential (borderline
carcinomas)

- Germ cell tumors, sex cord-stromal tumors, carcinosarcomas, mixed mullerian tumors or
carcinosarcomas, metastatic carcinomas from sites other than the ovary, and low
malignant potential tumors including so called micropapillary serous carcinomas.

- Synchronous primary endometrial cancer or history of primary endometrial cancer.

- Evidence of any other invasive malignancies present within the 3 years before this
study, with the exception of non-melanoma skin cancer and other specific malignancies
as noted above.

- Any prior treatment, other than initial debulking surgery, for the cancer being
treated in this study.

- Patients may have received prior adjuvant chemotherapy for localized breast cancer,
if the therapy was completed at least 3 years before registration in this study and
if the patient remains free of recurrent or metastatic disease.

- Prior radiotherapy to any portion of the abdominal cavity or pelvis.

- Prior radiation for localized cancer of the breast, head and neck, or skin is
permitted, if it was completed at least 3 years before registration in this study and
if the patient remains free of recurrent or metastatic disease.

- Administration of other investigational drugs within 26 weeks before the first
treatment in this study. Toxic manifestations of previous treatments (except
alopecia) must have been stable for 4 weeks.

- Presence of active hepatitis, either acute or chronic.

- Presence of active infection requiring antibiotic or antiviral therapy.

- Pregnant women or nursing mothers.